Rituximab therapy in patients with resistant rheumatoid arthritis: Real-life experience

Rheumatology

Volumn 46, Issue 6, 2007, Pages 980-982

  Jois, Rammi N ^a   Masding, A ^a   Somerville, M ^a   Gaffney, K ^a   Scott, D G I ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Rheumatoid arthritis; Rituximab

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MALE; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PERSONAL EXPERIENCE; POLYPHARMACY; PRIORITY JOURNAL; RETREATMENT; RHEUMATOID ARTHRITIS; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447312703     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel453     Document Type: Article

References (14)

1. Gabriel S, Crowson CS, Kremers HM et al. Survival in rheumatoid arthritis: A population based analysis over 40 years. Arthritis Rheum 2003;48:54-8.
2. Lipksy PE, Van der Heijde DM, St Clair EW et al. Infliximab and Methotrexate in the treatment of rheumatoid arthritis. Anti-tumour necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
3. Moreland LW, Schiff MF, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis: A randomized controlled trial. Ann Intern Med 1999;130:478-86.
4. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
5. Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002;14:204-11.
6. Edwards JC, Szczepanski J, Filipowicz-Sosnowska A et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
7. Cohen SB, Emery P, Greenwald MW et al. for the REFLEX trial group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:2793-806.
8. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. for the DANCER study group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
9. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum 1988;31:315-24.
10. van Gestel AM, Prevoo ML, van't Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis; comparison with the preliminary American College of Rheumatology and the World Health Organisation/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
11. Beaton DE, Bombardier C, Katz JN et al. Looking for important change/differences in studies of responsiveness; OMERACT MCID Working Group. Outcome measures in rheumatology; Minimal clinically important difference. J Rheumatol 2001;28:400-5.
12. Keystone E, Fleischmann R, Emery P et al. Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF tnhibitors. Arthritis Rheum 2006;54 (9 Suppl):S328.
13. van Vollenhoven RF, Cohen S, Pavelka K et al. Response to rituximab in patients with rheumatoid arthritis is maintained by repeat therapy: Results of an open-label trial. Arthritis Rheum 2006;54(9 Suppl):SAT0197.
14. Emery P, Furst DE, Ferraccioli G et al. Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs. Ann Rheum Dis 2006;65(Suppl II):OP0017.